文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

尼塞韦单抗引入对巴伦西亚自治区呼吸道合胞病毒的有效性:初步评估

Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.
PubMed 文献 · Vaccine · 2024-06-03

在西班牙巴伦西亚自治区,2023-2024季节引入长效单克隆抗体尼塞韦单抗,对高风险儿童和6月龄以下儿童进行普遍暴露前预防。研究评估其影响、覆盖率和有效性,结果显示接种运动覆盖率达88.5%,有效性为73.7%。分析超过27,000名易感儿童(超过24,000名已免疫)表明,免疫儿童RSV发病率较未免疫儿童降低三倍;预防一例需免疫人数(NNI)为63;免疫儿童急性呼吸道感染住院率几乎为未免疫儿童的一半(0.9% vs 1.6%)。

要点

  • 尼塞韦单抗接种运动覆盖率达88.5%,有效性为73.7%。
  • 免疫儿童RSV发病率较未免疫儿童降低三倍,NNI为63。
  • 免疫儿童急性呼吸道感染住院率为0.9%,未免疫儿童为1.6%。

核心结论

  • 这些初步结果展示了该公共卫生干预措施的初步积极影响。

研究设计与样本

  • 本研究评估尼塞韦单抗在巴伦西亚自治区2023-2024季节引入后的影响、覆盖率和有效性。
  • 分析超过27,000名易感儿童,其中超过24,000名已免疫。

主要发现

  • 接种运动覆盖率达88.5%,有效性为73.7%。
  • 免疫儿童RSV发病率较未免疫儿童降低三倍。
  • 预防一例需免疫人数(NNI)为63。
  • 免疫儿童急性呼吸道感染住院率为0.9%,未免疫儿童为1.6%,免疫儿童几乎低两倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) represents a high burden of disease in children and the primary cause of hospitalization, especially in children under 1 year old. In the Valencian Community (Spain), nirsevimab, a long-acting monoclonal antibody, was introduced for the RSV 2023-2024 season as a universal pre-exposure prophylaxis for high-risk children and those under 6 months old. This study examines its impact, coverage, and effectiveness. The campaign achieved 88.5 % coverage and 73.7 % of effectiveness. Analysis of over 27,000 susceptible children (over 24,000 immunized), showed that those immunized exhibited a threefold reduction in RSV incidence compared to non-immunized ones. To prevent one case, the number needed to immunize (NNI) was 63. Hospitalizations due to acute respiratory infections were almost two times lower in immunized children compared to non-immunized ones (0.9 % vs 1.6 %, respectively). These first results showcase the preliminary positive impact of this public health intervention.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Estrella-Porter P, Blanco-Calvo C, Lameiras-Azevedo AS, et al. Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment. Vaccine. 2024. PMID: 38834430. doi:10.1016/j.vaccine.2024.05.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。